Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SF 1126

Next Previous
X
Search
Drug Profile

SF 1126

Alternative Names: SF1126

Latest Information Update: 28 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Semafore Pharmaceuticals
  • Developer New Approaches to Neuroblastoma Therapy Consortium; SignalRx Pharmaceuticals
  • Class Antineoplastics; Drug conjugates; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; DNA-activated protein kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • No development reported Liver cancer; Lymphoproliferative disorders; Multiple myeloma; Neuroblastoma; Solid tumours

Most Recent Events

  • 28 Jun 2022 No recent reports of development identified for phase-I development in Liver-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 29 Jun 2020 SignalRX Pharmaceuticals terminates phase I trial in Liver cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) (IV) in USA (NCT03059147)
  • 28 Apr 2020 No recent reports of development identified for phase-I development in Liver-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top